Research Type: Extramural
Prof Maria Kavallaris and team aim to develop a precision treatment approach for children with high-risk neuroblastoma. Researchers will identify genes that neuroblastoma cells depend on to grow and survive, and design therapies that switch off these genes using gene silencing technology.
Dr Grundy and his team are looking for a new way to make BCG treatment more tolerable for patients. The team have already identified that the nerves in the bladder become overly sensitive during BCG therapy, reacting much more strongly to normal bladder activity.
We are pleased to announce the recipient of the 2025 Sally Crossing AM Award, Professor Keall, who leads the Image X Institute at the University of Sydney, for engaging consumers throughout his research which has positively impacted the lives of millions of cancer patients.
Professor Selth and his team have developed a new CDK inhibitor, called AU2-94. Preliminary evidence suggests that AU2-94 effectively blocks growth of breast and prostate cancer cells without causing significant toxicity.
Dr Cohen and his team have identified two small-molecule drugs that inhibit the action of telomerase, and this project aims to advance the efficacy and safety of these drugs.
Dr Teh and her team are developing a novel approach to immunotherapy that targets a different type of white blood cell, called a regulatory T cell. This project aims to target ‘suicide genes’ to kill regulatory T cells that are surrounding the tumour.
Professor Hondermarck and his team aim to enhance the efficacy of current Glioblastoma treatments by repurposing a drug that is already in clinical trials for its ability to protect the nervous system from damage.
Associate Professor Vittorio and his team discovered that brain cancers, such as DIPG, are addicted to copper and that using non-toxic drugs to reduce the levels of copper can kill the cancer cells.
Professor Pimanda and his team have discovered that there are key differences in the cancer cells between patients who respond to chemotherapy compared to those who don’t.
This project will repurpose an existing cancer drug, Entrectinib, to treat HER2+ breast cancers that are resistant to current anti-HER2 targeted therapies.